Upon completion of the activity, participants should be able to:
This educational initiative is intended for the Primary Care Team.
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.
The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.
First
MI
Last
Credentials
Position
Institution
Role
Disclosure(s)
Cecilia
C.
Low Wang
MD
Professor of Medicine
University of Colorado Anschutz Medical Campus School of Medicine
Speaker/Moderator
Dexcom Inc (Self) : Research Grant (Status: Ongoing)
Rifka
Schulman-Rosenbaum
MD, FACE, CNSC
Director of Inpatient Diabetes, Associate Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism Long Island Jewish Medical Center, and Barbara Zucker School of Medicine at Hofstra/Northwell
Nothing to disclose
Lawrence
Blonde
MD, FACP, MACE
Physician
Ochsner Medical Center
Speaker
AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- No activities in the past 24 months); Corcept (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Gilead Sciences, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Janssen () : Honorarium, speaker; Lyndra Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck & Co (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Salix (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing)
Guillermo
E.
Umpierrez
MD, MACP, CDCES, FACE
Emory University
Astra Zeneca (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Novo Nordisk (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Terminated --- December 2020), University Grants/Research Support (Status: Terminated --- December 2020); Sanofi,Merck, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim (Self) : Received grant support (to Emory university) for investigator-initiated research studies from Sanofi, Novo Nordisk, Astra Zeneca, Merck and Boehringer Ingelheim. (Status: Terminated --- January 2019), Research Grant (Status: Terminated --- January 2019)
Archana
Sadhu
MD, FACE
Director, System Diabetes Program and Director, Transplant Endocrinology
Houston Methodist
Abbott (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Rodolfo
J.
Galindo
Abbott Diabetes (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2018); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Eli Lilly (Self) : Research Grant (Status: Ongoing); Novo Nordisk (Self) : University Grants/Research Support (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Valeritas (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2019); Weight Watchers (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Neda
Rasouli
University of Colorado
Moderator
Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
Katherine
R.
Tuttle
MD, FASN, FACP, FNKF
University of Washington
AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eli Lilly (Self) : Honorarium (Status: Ongoing); Gilead (Self) : Grant/Research Support (Status: Ongoing); Goldfinch Bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing); Travere (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
Natasa
Janicic Kahric
Associate Professor
Medstar Georgetown University Hospital
DEXCOM (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Scott
D.
Isaacs
MD, FACP, FACE
Adjunct Assistant Professor of Medicine
Emory University School of Medicine
Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)
Kenneth
Cusi
Chief of the Division of Endocrinology
UFL
Allergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.